-

11:50:40 AM

LLY Stock News

LLY - Lilly(Eli) & Co

01/20/22 10:00 AM

NYSE : LLY

earnings

Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2021 Financial Results Announcement

Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2021 financial results on Thursday, Feb. 3, 2022. Lilly will also conduct a conference call on that day with the investment community and media to further detail the

RHEA-AI

neutral

01/06/22 2:00 PM

NYSE : LLY

conferences

Lilly to Participate in the J.P. Morgan Healthcare Conference

Eli Lilly and Company (NYSE: LLY) will participate at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, Jan. 11, 2022. David A. Ricks, Lilly's chairman and CEO, will participate in a virtual fireside chat at 4:30 p.m. Eastern time.A

RHEA-AI

neutral

01/06/22 6:45 AM

NYSE : LLY

Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications

Eli Lilly and Company (NYSE: LLY) has acquired exclusive rights to Entos Pharmaceuticals' Fusogenix nucleic acid delivery technology to research, develop and commercialize nucleic acid products targeting the central and peripheral nervous

RHEA-AI

neutral

12/21/21 12:01 AM

NYSE : LLY

clinical trial

Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study

Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids (TCS) in people with moderate-to-severe atopic dermatitis (AD) in Eli Lilly and Company's (NYSE: LLY) third pivotal Phase 3 trial

RHEA-AI

neutral

12/15/21 6:45 AM

NYSE : LLY

Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting

Eli Lilly and Company (NYSE: LLY) is providing extensive updates across its research and development (R&D) programs to highlight the company's strong pipeline and potential for future growth. At an investment community meeting today, the company is

RHEA-AI

neutral

12/14/21 5:00 PM

NYSE : LLY

clinical trial

Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022

Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary endpoint of clinical remission and all key secondary endpoints at one year in LUCENT-2, a Phase 3 maintenance study evaluating the efficacy and safety of mirikizumab for

RHEA-AI

neutral

12/13/21 3:35 PM

NYSE : LLY

dividends

Lilly Announces 15 Percent Dividend Increase, First-Quarter 2022 Dividend

The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15 percent increase in its quarterly dividend and declared a dividend for the first quarter of 2022 of $0.98 per share on outstanding common stock.The dividend is payable

RHEA-AI

neutral

12/13/21 6:00 AM

NYSE, Nasdaq : LLY, FHTX

Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc. (Nasdaq: FHTX), today announced a strategic collaboration to create novel oncology medicines by applying

RHEA-AI

neutral

12/12/21 9:30 AM

NYSE : LLY

clinical trial

Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced updated clinical data from the pirtobrutinib global Phase 1/2 BRUIN clinical trial in patients with chronic lymphocytic leukemia (CLL), small

RHEA-AI

neutral

12/10/21 6:30 AM

NYSE : LLY

Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders

Eli Lilly and Company (NYSE: LLY) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders.Under the terms of

RHEA-AI

positive

1 2 3 4 5 6 7 8 9 10 Next

LLY Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.lilly.com
CeoDavid Ricks
Security nameLilly(Eli) & Co
Issue typecs
SectorManufacturing
Sic code2834
Employees2020
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
AddressLilly Corporate Ctr
StateIndiana
CityIndianapolis
Zip46285-0001
CountryUS
Phone13172762000

LLY Description:

Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. It was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today it remains true to that mission in all its work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.